Biochemie and Pathobiochemie 7th Springer Berlin, Heidelberg, New York 2003 
Samuelsson B. Morgenstern R. Jakobsson P. J. Membrane prostaglandin E synthase-1: a novel therapeutic target Pharmacol. Rev. 2007 59 
Mehrotra S. Morimiya A. Agarwal B. Konger R. Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy J. Pathol. 2006 208 
Friesen R. W. Mancini J. A. Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target J. Med. Chem. 2008 51 
Thoren S. Jakobsson P. J. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4 Eur. J. Biochem. 2000 267 
Quraishi O. Mancini J. A. Riendeau D. Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids Biochem. Pharmacol. 2002 63 
Riendeau D. Aspiotis R. Ethier D. Gareau Y. Grimm E. L. Guay J. Guiral S. Juteau H. Mancini J. A. Methot N. Rubin J. Friesen R. W. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886 Bioorg. Med. Chem. Lett. 2005 15 
AbdulHameed M. D. Hamza A. Liu J. Huang X. Zhan C. G. Human microsomal prostaglandin E synthase-1 (mPGES-1) binding with inhibitors and the quantitative structure&#8211;activity correlation J. Chem. Inf. Model. 2008 48 
Cote B. Boulet L. Brideau C. Claveau D. Ethier D. Frenette R. Gagnon M. Giroux A. Guay J. Guiral S. Mancini J. Martins E. Masse F. Methot N. Riendeau D. Rubin J. Xu D. Yu H. Ducharme Y. Friesen R. W. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors Bioorg. Med. Chem. Lett. 2007 17 
Claveau D. Sirinyan M. Guay J. Gordon R. Chan C. C. Bureau Y. Riendeau D. Mancini J. A. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model J. Immunol. 2003 170 
San Juan A. A. Cho S. J. 3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors J. Mol. Model. 2007 13 
Jakobsson P. J. Morgenstern R. Mancini J. Ford-Hutchinson A. Persson B. Common structural features of MAPEG&#8212;a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism Protein Sci. 1999 8 
Jegerschold C. Pawelzik S. C. Purhonen P. Bhakat P. Gheorghe K. R. Gyobu N. Mitsuoka K. Morgenstern R. Jakobsson P. J. Hebert H. Structural basis for induced formation of the inflammatory mediator prostaglandin E2 Proc. Natl. Acad. Sci. U.S.A. 2008 105 
Rorsch F. Wobst I. Zettl H. Schubert-Zsilavecz M. Grosch S. Geisslinger G. Schneider G. Proschak E. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol J. Med. Chem. 2010 53 
Koeberle A. Zettl H. Greiner C. Wurglics M. Schubert-Zsilavecz M. Werz O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase J. Med. Chem. 2008 51 
Hessler G. Baringhaus K.-H. The scaffold hopping potential of pharmacophores Drug Discovery Today: Technol. 2010 7 
K&#246;berle A. Zettl H. Greiner C. Wurglics M. Schubert-Zsilavecz M. Werz O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase J. Med. Chem. 2008 51 
Int. Pat. Appl. PCT WO 2005/123673 A1 29 Dec 2005 
Int. Pat. Appl. PCT WO 2005/123675 A1 29 Dec 2005 
Edwards B. S. Bologa C. Young S. M. Balakin K. V. Prossnitz E. R. Savchuck N. P. Sklar L. A. Oprea T. I. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists Mol. Pharmacol. 2005 68 
Rohrer S. G. Baumann K. Maximum unbiased validation (MUV) data sets for virtual screening based on PubChem bioactivity data J. Chem. Inf. Model. 2009 49 
Chen C. Y.-C. Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping J. Taiwan Inst. Chem. Eng. 2009 40 
Celotti F. Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept Pharmacol. Res. 2001 43 
Koeberle A. Siemoneit U. Buhring U. Northoff H. Laufer S. Albrecht W. Werz O. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1 J. Pharmacol. Exp. Ther. 2008 326 
Peters-Golden M. Henderson W. R. Jr. Leukotrienes N. Engl. J. Med. 2007 357 
Hopkins A. L. Network pharmacology: the next paradigm in drug discovery Nature Chem. Biol. 2008 4 
Fischer L. Szellas D. Radmark O. Steinhilber D. Werz O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors FASEB J. 2003 17 
Werz O. Burkert E. Samuelsson B. Radmark O. Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes Blood 2002 99 
